10-Q: Zynex Reports Q1 2025 Results: Revenue Declines Amid TriCare Payment Suspension

Zynex's Q1 2025 revenue decreased by 43% year-over-year due to a temporary payment suspension from TriCare and a decline in device orders.

Summary

• Zynex, Inc. reported a net revenue of $26.6 million for the three months ended March 31, 2025, a 43% decrease compared to $46.5 million for the same period in 2024.
• The company experienced a net loss of $10.4 million for Q1 2025, a stark contrast to the net income of $10,000 reported in Q1 2024.
• Device revenue decreased by 15% to $11.9 million, while supplies revenue decreased by 55% to $14.7 million.
• The decline in revenue is primarily attributed to a temporary payment suspension from TriCare, which historically represents 20-25% of annual revenue, and a 3% decline in device orders.
• The company reduced its overall staff by approximately 15% to align with current revenue, expecting annual savings of approximately $35 million.
• Cash used in operating activities was $10.5 million for Q1 2025, compared to cash provided by operating activities of $2.1 million for Q1 2024.
• Working capital decreased to $40.1 million as of March 31, 2025, from $58.3 million as of December 31, 2024.
• The company is involved in a securities fraud class action lawsuit filed on March 20, 2025.
• The company's board approved the purchase of 1,700,000 shares of the company's common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on March 13, 2025, of $2.905 per share for $4.9 million.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, net loss, and a payment suspension from a major payer. The ongoing lawsuit and material weakness in internal controls further contribute to the negative sentiment.

Positives

• Zynex implemented a staff reduction of approximately 15%, expected to result in annual savings of approximately $35 million.
• The company believes it has good evidence to get payments reinstated from Tricare, with a response expected in June 2025.
• The company's board approved the purchase of 1,700,000 shares of the company's common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on March 13, 2025, of $2.905 per share for $4.9 million.

Negatives

• Zynex experienced a significant 43% decrease in net revenue for Q1 2025.
• The company reported a net loss of $10.4 million for Q1 2025.
• A temporary payment suspension from TriCare significantly impacted revenue.
• The company identified a material weakness related to Information Technology General Controls (ITGCs).
• A securities fraud class action lawsuit was filed against the company, its CEO, and CFO on March 20, 2025.

Risks

• The temporary payment suspension from TriCare could have a material adverse impact on revenues and profits.
• The company faces risks associated with new duties, tariffs, and trade barriers.
• The securities fraud class action lawsuit could result in significant damages and legal expenses.
• The identified material weakness in internal control over financial reporting could lead to material misstatements in financial statements.
• The company's effective tax rate has the potential for volatility due to various factors.

Future Outlook

The company believes its cash and cash equivalents, together with anticipated cash flow from operations, will be sufficient to meet its working capital and capital expenditure requirements for at least the next twelve months.

Industry Context

The medical device industry is subject to regulatory scrutiny and reimbursement challenges, as evidenced by the TriCare payment suspension. Companies in this sector must navigate complex billing and reimbursement processes while maintaining compliance with FDA regulations.

Comparison to Industry Standards

• It is difficult to compare Zynex's results directly to industry standards without specific competitor data.
• However, the decline in revenue and shift to a net loss are concerning and warrant further investigation into the factors affecting the company's performance.
• The temporary payment suspension from TriCare is a significant event that requires close monitoring to assess its long-term impact.
• The company's cost-cutting measures, including staff reductions, are a common response to declining revenue in the industry.

Legal Proceedings

• A securities fraud class action lawsuit was filed against the Company, its current CEO Thomas Sandgaard, and current CFO Daniel Moorhead, in the U.S. District Court for the District of Colorado, captioned Tuncel v. Zynex Inc. et al., No. 25-cv-913.

Related Party Transactions

• On March 13, 2025, the disinterested Board and Audit Committee approved the purchase of 1,700,000 common shares of ZYXI from Mr. Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on March 13, 2025 of $2.905 per share, resulting in a total transactional value of $4,938,500.

Stakeholder Impact

• Shareholders are negatively impacted by the decline in revenue, net loss, and ongoing lawsuit.
• Employees were impacted by the staff reduction of approximately 15%.
• Customers (patients) may experience disruptions in service due to the TriCare payment suspension.

Next Steps

• The company expects a response from TriCare in June 2025 regarding the payment suspension.
• The company is in the process of developing and implementing remediation plans to address the material weakness in internal control over financial reporting.

Key Dates

Keywords

Zynex, revenue, TriCare, payment suspension, medical devices, financial results, Q1 2025, net loss, stock repurchase, lawsuit